Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.

Viruses - 14 Feb 2022

Hu Ye-Fan, Hu Jing-Chu, Chu Hin, Yau Thomas, Zhang Bao-Zhong, Huang Jian-Dong

Abstract excerpt

Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against epitopes. In our database, 132 epitopes of the 120 antibodies are classified into five groups, namely NTD, RBD-1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Factual

Share to Epitopes

Share to Immunoglobulin G

Share to Neutralization Tests

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 35215983
DOI: 10.3390/v14020390
PMCID: PMC8876352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.PMID 35215983Read ↗

Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized miceSemantic proximity Read ↗

SARS-CoV-2 Omicron Variants and Their Susceptibility Towards Monoclonal Antibodies in a Swedish Cohort During 2022-23, Studied by Next-Generation SequencingSemantic proximity Read ↗

A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in TherapiesSemantic proximity Read ↗

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read ↗

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolateSemantic proximity Read ↗

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralizationSemantic proximity Read ↗

Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodiesSemantic proximity Read ↗

Structural insight into antibody evasion of SARS-CoV-2 omicron variantSemantic proximity Read ↗

SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernSemantic proximity Read ↗

Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance.Semantic proximity Read ↗

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.